Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $137.37 million. The enterprise value is -$232.95 million.
| Market Cap | 137.37M |
| Enterprise Value | -232.95M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 68.01 million shares outstanding. The number of shares has decreased by -4.25% in one year.
| Shares Outstanding | 68.01M |
| Shares Change (YoY) | -4.25% |
| Shares Change (QoQ) | -2.42% |
| Owned by Insiders (%) | 14.22% |
| Owned by Institutions (%) | 88.48% |
| Float | 51.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.77 |
| PS Ratio | 0.35 |
| Forward PS | n/a |
| PB Ratio | 0.42 |
| P/FCF Ratio | 8.89 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.48 |
| Quick Ratio | 4.30 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.24 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.20% and return on invested capital (ROIC) is -24.77%.
| Return on Equity (ROE) | -18.20% |
| Return on Assets (ROA) | -15.30% |
| Return on Capital (ROIC) | -24.77% |
| Revenue Per Employee | $1.04M |
| Profits Per Employee | -$185,143 |
| Employee Count | 384 |
| Asset Turnover | 0.86 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $5.44 million in taxes.
| Income Tax | 5.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.88% in the last 52 weeks. The beta is -0.64, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.64 |
| 52-Week Price Change | -90.88% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 9.48 |
| Relative Strength Index (RSI) | 52.76 |
| Average Volume (20 Days) | 2,975,277 |
Short Selling Information
The latest short interest is 4.57 million, so 6.72% of the outstanding shares have been sold short.
| Short Interest | 4.57M |
| Short Previous Month | 7.21M |
| Short % of Shares Out | 6.72% |
| Short % of Float | 8.87% |
| Short Ratio (days to cover) | 2.39 |
Income Statement
In the last 12 months, AMLX had revenue of $398.00 million and -$71.10 million in losses. Loss per share was -$1.07.
| Revenue | 398.00M |
| Gross Profit | 261.44M |
| Operating Income | -81.28M |
| Pretax Income | -65.66M |
| Net Income | -71.10M |
| EBITDA | -64.46M |
| EBIT | -65.66M |
| Loss Per Share | -$1.07 |
Balance Sheet
The company has $374.01 million in cash and $3.69 million in debt, giving a net cash position of $370.32 million or $5.45 per share.
| Cash & Cash Equivalents | 374.01M |
| Total Debt | 3.69M |
| Net Cash | 370.32M |
| Net Cash Per Share | $5.45 |
| Equity (Book Value) | 324.44M |
| Book Value Per Share | 4.77 |
| Working Capital | 318.90M |
Cash Flow
In the last 12 months, operating cash flow was $16.50 million and capital expenditures -$1.06 million, giving a free cash flow of $15.44 million.
| Operating Cash Flow | 16.50M |
| Capital Expenditures | -1.06M |
| Free Cash Flow | 15.44M |
| FCF Per Share | $0.23 |
Margins
Gross margin is 65.69%, with operating and profit margins of -20.42% and -17.86%.
| Gross Margin | 65.69% |
| Operating Margin | -20.42% |
| Pretax Margin | -16.50% |
| Profit Margin | -17.86% |
| EBITDA Margin | -16.20% |
| EBIT Margin | -16.50% |
| FCF Margin | 3.88% |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.25% |
| Shareholder Yield | 4.25% |
| Earnings Yield | -51.75% |
| FCF Yield | 11.24% |
Analyst Forecast
The average price target for AMLX is $5.20, which is 157.43% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.20 |
| Price Target Difference | 157.43% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | -51.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMLX has an Altman Z-Score of 0.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.82 |
| Piotroski F-Score | 4 |